NCT06444178View on ClinicalTrials.gov

Assessment of Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban, or Aspirin Plus REGN9933, or Aspirin Plus REGN7508 in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

224

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

April 7, 2025

Study Completion Date

July 9, 2025

Conditions
Healthy Volunteers
Interventions
DRUG

Aspirin

Oral administration

DRUG

REGN9933

Administered intravenous (IV)

DRUG

REGN7508

Administered IV

DRUG

Rivaroxaban

Oral administration

Trial Locations (1)

LS11 9EH

Fortrea Clinical Development, Leeds

All Listed Sponsors
lead

Regeneron Pharmaceuticals

INDUSTRY

NCT06444178 - Assessment of Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban, or Aspirin Plus REGN9933, or Aspirin Plus REGN7508 in Healthy Adult Participants | Biotech Hunter | Biotech Hunter